Developments Histogen completes enrollment in Phase 1b/2a alopecia trial Histogen (NASDAQ:HSTO) completed patient enrollment in its Phase 1b/2a clinical trial evaluating HST 001 for the treatment of androgenic alopecia in men. The trial enrolled 36 subjects with male pattern hair loss who... July 14, 2020